Bloomberg Talks Novo Nordisk CEO Mike Doustdar Talks Drug Sales
Nov 5, 2025
Mike Doustdar, the newly appointed CEO of Novo Nordisk, faces the challenge of disappointing sales for their key drugs, Wegovy and Ozempic. He discusses strategic priorities, including expanding patient access and the rationale behind the recent acquisition of Metzera to enhance their product offerings. Doustdar also touches on competitive dynamics with Eli Lilly and emphasizes the importance of adapting to patient preferences between pills and injections. Additionally, he shares insights into engaging with the U.S. administration on pricing negotiations.
AI Snips
Chapters
Transcript
Episode notes
Long-Term Market Opportunity
- Mike Doustdar frames Novo Nordisk's situation as a marathon, not a sprint, citing large unmet patient need.
- He expects to expand the market by reaching patients not currently on medications.
Quarterly Headwinds Despite YTD Growth
- Doustdar explains third-quarter trends point to a headwind that may push Q4 into negative growth.
- He notes 15% sales growth and 10% profit growth year-to-date versus peers despite the quarterly slowdown.
Prepare To Outperform Competition
- Doustdar says Novo must prepare to outperform incoming competition from other pharma companies.
- He emphasizes positioning the company to handle clear headwinds for shareholders.